Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer.

ABSTRACT: Immunotherapy offers a distinctive mechanism of action compared to traditional treatments, arising from additional value dimensions that may not be captured in standard health technology assessments. Cancer patients may have the expectation that immunotherapy provides durable, long-term survival gains. Moreover, some patients may be willing to take a 'risk' to undergo immunotherapy to achieve better survival outcomes. We reviewed quantitative methods that explored patients' risk preferences in their non-small cell lung cancer (NSCLC) treatment choices, in PubMed (MEDLINE), from January 1, 2015, until July 1, 2022. The consideration of a value dimension ('hope') based on patients' risk-seeking preferences is specifically addressed for the valuation of immune checkpoint inhibitors in NSCLC.

SUBMITTER: Zaim R 

PROVIDER: S-EPMC10032401 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature